ZNTL vs. PRTA, TERN, PRME, HUMA, AQST, SNDL, HRTX, AURA, ALT, and CTOR
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), Aquestive Therapeutics (AQST), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Altimmune (ALT), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.
Zentalis Pharmaceuticals vs. Its Competitors
Prothena (NASDAQ:PRTA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.
97.1% of Prothena shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Prothena had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.00 beat Prothena's score of -0.16 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Zentalis Pharmaceuticals' return on equity.
Prothena presently has a consensus target price of $31.50, suggesting a potential upside of 383.13%. Zentalis Pharmaceuticals has a consensus target price of $8.37, suggesting a potential upside of 558.79%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Prothena.
Prothena has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Prothena has higher revenue and earnings than Zentalis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Prothena beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ZNTL) was last updated on 7/9/2025 by MarketBeat.com Staff
Free ZNTL Stock Alerts